Fisogatinib blueprint. Active, not recruiting.

Fisogatinib blueprint The study consists of 3 parts, a dose-escalation part Fisogatinib was well tolerated; most adverse events were manageable, grade 1/2 gastrointestinal events, primarily diarrhea, nausea, and vomiting. 69%. Heavy reliance on partners for collaboration revenues remains a concern. the disease, Blueprint Medicines now estimates there are approximately 75,000 patients with SM in the major markets, which consist of the United States, France, Germany, Italy, Spain, United Kingdom and Japan. Get access to cutting edge treatment via Blueprint Medicines Corporation (BPMC) Historical ROE (quarterly & annually) How has BPMC ROE performed in the past?. . Blueprint Medicines and Roche have co-exclusive rights to develop and commercialize pralsetinib in the U. In this presentation, forward-looking statements include, without limitation, statements regarding Blueprint Medicines’ 2020 key milestones; Blueprint Medicines’ plans, strategies, timelines and expectations for the preclinical and clinical development and commercialization of AYVAKIT™ (avapritinib), pralsetinib, fisogatinib, BLUEPRINT MED. Drug class: FGFR4 inhibitor. Anticipated Duration (Months) 17. Medical writing support was provided by Natasha Tracey, PhD, and editorial News for fisogatinib (BLU-554) / CStone Pharma, Blueprint Medicines. Read the press release here. Kim, News for fisogatinib (BLU-554) / CStone Pharma, Blueprint Medicines. Active, not recruiting. Contact us to learn more about our Premium Content: News alerts, weekly reports and conference planners . The study consists of 3 parts, a dose-escalation part Rapidly advancing pipeline DISCOVERY LATE-STAGE DEVELOPMENT EARLY-STAGE DEVELOPMENT REGULATORY SUBMISSION APPROVED Cancer immunotherapy 1CStone Pharmaceuticals has exclusive rights to develop and commercialize avapritinib, pralsetinib and fisogatinib in Mainland China, Hong Kong, Macau and Taiwan. Received conditional 2CStone Pharmaceuticals has exclusive rights to develop and commercialize avapritinib, pralsetinib and fisogatinib in Mainland China, Hong Kong, Macau and Taiwan. 1 to 25 Of 68 Go to page . Home Next Prev. Apply to this Phase 1 clinical trial treating Hepatocellular Carcinoma. The obtained insights may be useful (Blueprint Medicines Corporation, Cambridge, MA) contributed to the BLU-701 program. 2Approved in Blueprint Medicines Corporation (BPMC) Historical Enterprise Value (quarterly & annually) How has BPMC Enterprise Value performed in the past?. Two drugs are currently in phase I: PRN1371 (Principia Biofarma, NCT02608125) and ASP5878 (Astellas, NCT02038673). , and Roche has exclusive rights to develop and commercialize pralsetinib outside the U. , Nov. Aldehyde-containing roblitinib CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company focused on developing and commercializing immuno-oncology and precision Four of the existing FGFR4 specific small molecule inhibitors, including BLU-554 (also known as Fisogatinib, a modified version of BLU-9931) (Hagel, et al. CS1001 is an investigational anti-PD-L1 monoclonal antibody being developed by CStone for multiple tumor types Neil BIFULCO, Scientist | Cited by 432 | of Blueprint Medicines, Massachusetts | Read 13 publications | Contact Neil BIFULCO Discover insights from Blueprint Medicines's annual reports and investor relations material with Quarterlytics' easy-to-use platform. , Suzhou, China Aberrant FGF19-FGFR4 signaling identified as a potential HCC driver FGF19 is a mitogen that signals via FGFR4 and KLB Normal liver and HCC consistently express FGFR4 and KLB; but only HCC aberrantly ex- presses FGF19 ligand (27% were positive for 2CStone Pharmaceuticals has exclusive rights to develop and commercialize avapritinib, pralsetinib and fisogatinib in Mainland China, Hong Kong, Macau and Taiwan. View duration, location, compensation, and staffing details. CS1001 is an investigational anti-PD-L1 monoclonal antibody being developed by CStone for multiple tumor types clinical trials or the development of the Company's drug candidates, including avapritinib for additional indications, pralsetinib , fisogatinib and BLU-263, or the licensed drug candidate ; the Company's advancement of multiple early-stage efforts; the Company's ability to successfully demonstrate the efficacy and safety of its drug candidates and gain approval of its Dosed the first patient in a Phase 1b/2 trial evaluating fisogatinib in combination with CS1001 for the treatment of locally advanced or metastatic HCC, under Blueprint Medicine’s collaboration with CStone Pharmaceuticals. The pipeline for Blueprint Medicines is expansive with many programs in the pipeline. The proposed indication Blueprint Medicines Corporation, Cambridge, United States; 9. i. Fisogatinib (BLU-554) Blueprint: FGFR4: Phase I. These results validate the oncogenic driver role of the FGFR4 Fisogatinib (BLU-554) is a potent and selective inhibitor of FGFR4 and demonstrates clinical benefit and tumor regression in HCC patients with aberrant FGF19 expression. May 06, 2024 Discovery of 2,6-Naphthyridine Analogues as Selective FGFR4 Inhibitors for Hepatocellular Carcinoma. This study will evaluate the safety, tolerability, pharmacokinetic and efficacy of fisogatinib (formerly known as BLU-554) in combination with CS1001 in patients Blueprint Medicines has an exclusive collaboration and license agreement with CStone Pharmaceuticals for the development and commercialization of pralsetinib, avapritinib and fisogatinib in Mainland China, Hong Kong, Macau and Taiwan. FGF19 positive advanced hepatocellular carcinoma. The proposed indication for the MAA is CStone and Blueprint enrolled the first patient in a trial exploring the combination of the FGFR4 inhibitor fisogatinib and a PD-L1 inhibitor. Funder types. , Suzhou, China Aberrant FGF19-FGFR4 signaling identified as a potential HCC driver FGF19 is a mitogen that signals via FGFR4 and KLB Normal liver and HCC consistently express FGFR4 and KLB; but only HCC aberrantly ex- presses FGF19 ligand (27% were positive for Blueprint Medicines Corporation BPMC reported a fourth-quarter 2023 loss of $1. The development of FGFR inhibitors represents an edifying example of the rapid evolution in the field of targeted oncology, with 10 different FGFR tyrosine kinase inhibitors actually under clinical Blueprint Medicines (BPMC) and partner CStone begin dosing in the phase Ib/II study on fisogatinib and CS1001 combo for treating patients with locally advanced/metastatic hepatocellular carcinoma. S. These 2 molecules have been CStone Pharma of Suzhou and Boston's Blueprint Medicines have started a China Phase Ib/II trial that combines a precision therapy with an immunotherapy to treat hepatocellular carcinoma. Industry. 65 in the year-ago CStone Pharmaceuticals and Blueprint Medicines Initiate Phase 1b/2 Clinical Trial of Fisogatinib in Combination with CS1001 for Patients with Hepatocellular Carcinoma -- Study to assess potential Emily ROZSAHEGYI, Manager | Cited by 109 | of Blueprint Medicines, Massachusetts | Read 6 publications | Contact Emily ROZSAHEGYI Blueprint Medicines has an exclusive collaboration and license agreement with CStone Pharmaceuticals for the development and commercialization of pralsetinib, avapritinib and fisogatinib in Mainland China, Hong Kong, Macau and Taiwan. 48B Enterprise Value has changed 21. • Announce a comprehensive strategy to address a broad population of patients with SM and other mast cell disorders with the company’s drug fisogatinib (BLU-554, CS3008) - BioCentury Product Profiles for the biopharma industry Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. This prevents the activation of FGFR4, inhibits FGFR4-mediated signaling and leads to an inhibition of tumor cell proliferation in FGFR4 Discovered by Blueprint Medicines, fisogatinib is an investigational, potent and highly selective inhibitor of fibroblast growth factor receptor 4 (FGFR4) in clinical development for the treatment of advanced FGFR4-driven HCC. Precision oncology relies on the identification of molecular alterations, responsible for tumor initiation and growth, which are suitable targets of specific inhibitors. , 2015), H3B-6527 (Joshi, et al. Turner8, Yan Wu9, Xin Chen9, Jin Hu9, Yu Abstract. It was discovered by Blueprint Medicines [] (probably compound number 40 therein), and is being investigated for clinical anti-tumour efficacy in cancers that are driven by FGFR4 activation (for example, in liver cancers where the Rapidly advancing pipeline DISCOVERY LATE-STAGE DEVELOPMENT EARLY-STAGE DEVELOPMENT REGULATORY SUBMISSION APPROVED Cancer immunotherapy 1CStone Pharmaceuticals has exclusive rights to develop and commercialize avapritinib, pralsetinib and fisogatinib in Mainland China, Hong Kong, Macau and Taiwan. 5. Research Operations Manager at Blueprint Medicines | EMBA · Experience: Blueprint Medicines · Education: Quantic School of Business and Technology · Location: Cambridge · 217 connections First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma. We also thank the scientists at Wuxi AppTec for Rapidly advancing pipeline DISCOVERY LATE-STAGE DEVELOPMENT EARLY-STAGE DEVELOPMENT REGULATORY SUBMISSION APPROVED Cancer immunotherapy 1CStone Pharmaceuticals has exclusive rights to develop and commercialize avapritinib, pralsetinib and fisogatinib in Mainland China, Hong Kong, Macau and Taiwan. 6, 2020 /PRNewswire/ -- CStone Pharmaceuticals ('CStone', HKEX: 2616), a biopharmaceutical company focuse Blueprint Medicines and Roche have co-exclusive rights to develop and commercialize pralsetinib in the U. , 2015), H3B-6527 (Joshi et al. It was discovered by Blueprint Medicines [] (probably compound number 40 therein), and is being investigated for clinical anti-tumour efficacy in cancers that are driven by FGFR4 activation (for example, in liver cancers where the Fisogatinib Alternative Names: fisogatinib, blu-554, blu554, blu 554 Latest Update: 2024-05-05 Latest Update Note: PubMed Publication Fisogatinib: 一种FGFR4拮抗剂药物，由Blueprint Medicines Corp. , Suzhou, China Aberrant FGF19-FGFR4 signaling identified as a potential HCC driver FGF19 is a mitogen that signals via FGFR4 and KLB Normal liver and HCC consistently express FGFR4 and KLB; but only HCC aberrantly ex- presses FGF19 ligand (27% were positive for Oleg Schmidt-Kittler's 56 research works with 4,696 citations and 6,696 reads, including: Identifying FGFR2 fusions/rearrangements in cholangiocarcinoma patients using a novel cfDNA algorithm for SUZHOU, China and CAMBRIDGE, Mass. The acrylamide-containing FGFR4 inhibitor fisogatinib (Blueprint Medicines; BLU-554) is currently the subject of a phase II clinical trial (NCT04194801). com Blueprint Medicines and Roche have co-exclusive rights to develop and commercialize pralsetinib in the U. CStone Pharmaceuticals has exclusive rights to develop and commercialize avapritinib, pralsetinib and fisogatinib in Mainland China, Hong Kong, Macau and Taiwan. Fisogatinib was well tolerated; most adverse events were manageable, grade 1/2 gastrointestinal events, primarily diarrhea, nausea, and vomiting. Over the 2CStone Pharmaceuticals has exclusive rights to develop and commercialize avapritinib, pralsetinib and fisogatinib in Mainland China, Hong Kong, Macau and Taiwan. Company: Blueprint Medicines, CStone Pharma. Related drugs: ‹ erdafitinib (70) H3B-6527 (3) FGF401 (3) ABSK012 (1) BLU 9931 (1) ABSK011 (1) ASP5878 (0) This is a Phase 1, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of fisogatinib (formerly known as BLU- 554) administered orally in patients with FGF19 IHC+ hepatocellular carcinoma (HCC). SUZHOU, China and CAMBRIDGE, Mass. 7-not reached)] and 0% in FGF19-negative patients. Received conditional Megan A. 1 to 25 Of 58 Go to page . 65% with respect to the historical average. CStone Pharmaceuticals (Suzhou) Co. CS1001 is an investigational anti-PD-L1 monoclonal antibody being developed by CStone for multiple types of tumors. CORP. 2Approved in Bilanz, Marktkapitalisierung, Umsatz & Gewinn, Dividendenausschüttungen, Dividendenrendite und Termine zu Blueprint Medicines Um die volle Funktionalität der Webseite nutzen zu können, müssen Blueprint Medicines Corporation (Industry) 52. Received conditional marketing Comment: Fisogatinib (BLU-554) is an orally bioavailable, potent and highly selective fibroblast growth factor receptor 4 (FGFR4) inhibitor. Phase 1. , Jan. (NASDAQ:BPMC) enter into an exclusive collaboration and license agreement regarding the clinical development and commercialization of avapritinib, fisogatinib, and pralsetinib, as mono-therapies or in combination with other therapies, in Greater China including Hong Kong, Macau, and Taiwan. These results validate FGFR4 GlobalData’s premium database of Blueprint Medicines Corp Catalyst Calendar helps in proactively evaluating Blueprint Medicines Corp’s catalyst impacts to stay ahead of the competition, improve corporate planning, and bolster business development with Blueprint Medicines (BPMC) and partner CStone begin dosing in the phase Ib/II study on fisogatinib and CS1001 combo for treating patients with locally advanced/metastatic hepatocellular carcinoma. Synonyms : fibroblast growth factor receptor 4 inhibitor blu-554, fgfr4 inhibitor blu-554, fibroblast growth factor receptor 4 inhibitor blu-554, blu-554 Rapidly advancing pipeline DISCOVERY LATE-STAGE DEVELOPMENT EARLY-STAGE DEVELOPMENT REGULATORY SUBMISSION APPROVED Cancer immunotherapy 1CStone Pharmaceuticals has exclusive rights to develop and commercialize avapritinib, pralsetinib and fisogatinib in Mainland China, Hong Kong, Macau and Taiwan. Conditions. 24. Locations. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. 66% ROE has changed-45. News for fisogatinib (BLU-554) / CStone Pharma, Blueprint Medicines. ORR objective response rate, DCR disease control rate, PFS progression-free survival, OS overall survival, DOR duration of Blueprint Medicines Corporation BPMC along with China’s CStone Pharmaceuticals announced that it has dosed the first patient in a phase Ib/II study evaluating its FGFR4 inhibitor fisogatinib in 1. Hatlen's 4 research works with 73 citations and 216 reads, including: Abstract 1279: Development of a selective CDK2-E inhibitor in CCNE driven cancers enrollment, plans and announcement of results regarding the ongoing and planned clinical trials for avapritinib, pralsetinib, fisogatinib and BLU-782 of Blueprint Medicines Corporation (the “Company”); plans and timelines for submitting marketing applications for avapritinib and pralsetinib, including expectations regarding the approval of any such Fisogatinib (formerly BLU 554 and also known as CS 3008) is an orally available, small molecule, potent, irreversible inhibitor type 4 fibroblast growth factor Fisogatinib - CStone Pharmaceuticals - AdisInsight Timothy Guzi's 20 research works with 933 citations and 2,078 reads, including: Evaluation of Protein Kinase cAMP-Activated Catalytic Subunit Alpha as a Therapeutic Target for Fibrolamellar Carcinoma Discovered by Blueprint Medicines, fisogatinib is an investigational, potent and highly selective inhibitor of fibroblast growth factor receptor 4 (FGFR4) in clinical development for the treatment of advanced FGFR4-driven HCC. , Ltd. Preclinical data has Dies ist eine Open-Label-First-in-Human (FIH)-Studie der Phase 1 zur Bewertung der Sicherheit, Verträglichkeit, Pharmakokinetik (PK), Pharmakodynamik (PD) und vorläufigen Fisogatinib (BLU-554) is a potent and selective inhibitor of FGFR4 and demonstrates clinical benefit and tumor regression in patients with HCC with aberrant FGF19 expression. 2015-001662-26 (EudraCT Number) BLU-554-1101 . Sr. November 04, 2023 Dual inhibition of FGFR4 and HER2/EGFR with Lapatinib improves targeting of Erk and Akt signaling in HER2+ breast cancer cells (SABCS 2023) - 此项试验将评估靶向治疗和癌症免疫治疗联合在局部晚期和转移性HCC患者中增强抗肿瘤活性的潜力。Fisogatinib是由Blueprint Medicines开发的一款在研的强效、高选择性成纤维细胞生长因子受体-4（FGFR4）抑制剂，用于治疗FGFR4驱动的晚期HCC。CS1001是一款由基石药业开发 Four of the existing FGFR4 specific small molecule inhibitors, including BLU-554 (also known as Fisogatinib, a modified version of BLU-9931) (Hagel et al. The IC50s for FGFR1-3 is 624-2203 nM. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT We evaluated fisogatinib (BLU-554), a highly potent and selective oral FGFR4 inhibitor, in a phase I dose-escalation/ dose-expansion study in advanced HCC using FGF19 expression measured by IHC as a biomarker for pathway activation. 45% with respect to the historical average. Drug Details. , Suzhou, China Aberrant FGF19-FGFR4 signaling identified as a potential HCC driver FGF19 is a mitogen that signals via FGFR4 and KLB Normal liver and HCC consistently express FGFR4 and KLB; but only HCC aberrantly ex- presses FGF19 ligand (27% were positive for fisogatinib (BLU-554) i. , 2017), FGF401 (also known as Roblitinib) (Zhou, et al. Identify trends, assess risk, and make informed investment decisions. View 41 locations. Take notes. Pharmaron, Inc. CS1001 is an investigational anti-PD-L1 monoclonal antibody being developed by CStone for multiple tumor types Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. 2. This is a Phase 1, open Fisogatinib is an orally bioavailable inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. The mean historical Enterprise Value of Blueprint Medicines Corporation over the last ten years is 3. Approved in the U. They are developing various drugs for the treatment of different types of cancers, including AYVAKIT, BLU 2CStone Pharmaceuticals has exclusive rights to develop and commercialize avapritinib, pralsetinib and fisogatinib in Mainland China, Hong Kong, Macau and Taiwan. 3. The study consists of 3 parts, a dose-escalation part (Part 1), an expansion part (Part 2) exploring Blueprint Medicines is a precision therapy company that develops medicines for genomically defined cancers and blood disorders. Over the past ten years (40 quarters), BPMC's ROE was at CAMBRIDGE, Mass. Eine Phase-1-Studie zur Bewertung der Sicherheit, Verträglichkeit, Pharmakokinetik, Pharmakodynamik und vorläufigen Wirksamkeit von BLU-554 bei Patienten mit hepatozellulärem Karzinom. It was discovered by Blueprint Medicines [] (probably compound number 40 therein), and is being investigated for clinical anti-tumour efficacy in cancers that are driven by FGFR4 activation (for example, in liver cancers where the Hier sollte eine Beschreibung angezeigt werden, diese Seite lässt dies jedoch nicht zu. Blueprint Medicin es retains all rights in the res t of the world. 2Approved in Fisogatinib and CStone's PD-L1 inhibitor CS1001 have complementary mechanisms of action that may offer durable clinical activity in patients with HCC," Andy Boral, MD, PhD, chief medical officer at Blueprint Medicines, said in a statement. DL-001 Kurs heute • Aktuelle Realtime Finanzdaten, Nachrichten und Informationen zur Aktie (2L9) • US09627Y1091 (A14SDD) • Gesundheit • Biotechnologie The acrylamide-containing FGFR4 inhibitor fisogatinib (Blueprint Medicines; BLU-554) is currently the subject of a phase II clinical trial (NCT04194801). Fisogatinib (BLU-554) is a potent and selective inhibitor of FGFR4 and demonstrates clinical benefit and tumor regression in patients with HCC with aberrant FGF19 expression. 3 months (95% CI, 3. Patients Per Site Per Month. Februar 2023 aktualisiert von: Blueprint Medicines Corporation. 2CStone Pharmaceuticals has exclusive rights to develop and commercialize avapritinib, pralsetinib and fisogatinib in Mainland China, Hong Kong, Macau and Taiwan. CS1001 is an investigational anti-PD-L1 monoclonal antibody being developed by CStone for multiple tumor types 2CStone Pharmaceuticals has exclusive rights to develop and commercialize avapritinib, pralsetinib and fisogatinib in Mainland China, Hong Kong, Macau and Taiwan. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the CStone Pharmaceuticals has exclusive rights to develop and commercialize avapritinib, pralsetinib and fisogatinib in Mainland China, Hong Kong, Macau and Taiwan. CT. , 2019) and INCB062079 (Ruggeri et al. Enrollment. 2Approved in Joseph L. 01B. The study consists of 3 parts. fisogatinib fisogatinib -Blueprint Medicines Corp Japan JP6104377 Jul-2033 -- Blueprint Medicines Corp Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) United States Margit Hagel's 14 research works with 483 citations and 917 reads, including: First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant Fibroblast Growth Factor 19 Signaling as a June, 2018 - CStone and Blueprint Medicines Corp. Phase 1 Study of Fisogatinib (BLU-554) in Patients (pts) with Advanced Hepatocellular Carcinoma (aHCC) Expressing FGF19: Preliminary Results from Chinese Pts in Part 3 of the Study Category: Hepatobiliary Pancreatic-Hepatic Cancer Shukui Qin1, Bo Li2, Jufeng Wang3, Aibing Xu4, Yabing Guo5, Weijia Fang6, Ying Cheng7, Christopher D. Blueprint Medicines (BPMC) and partner CStone begin dosing in the phase Ib/II study on fisogatinib and CS1001 combo for treating patients with locally advanced/metastatic hepatocellular carcinoma. Hepatocellular carcinoma is the most common disease being investigated in fisogatinib clinical trials . Fisogatinib was specifically designed by Blueprint Medicines to inhibit FGFR4 with exquisite selectivity, thereby sparing the paralogs FGFR1, FGFR2 and FGFR3. Blueprint Medicines retains development and commercial rights for all three licensed products in the rest of Blueprint Medicines (BPMC) and partner CStone begin dosing in the phase Ib/II study on fisogatinib and CS1001 combo for treating patients with locally advanced/metastatic hepatocellular carcinoma. Details and patient eligibility. in vitro biology team (Beijing, China) and WuXi AppTec oncology and immunology department (Shanghai, China) contributed to the in vivo and in vitro pharmacology data collection. Across doses, the overall response rate was 17% in FGF19-positive patients [median duration of response: 5. 04 and a loss of $2. Keywords: National Institutes of Health; National Center fo Fisogatinib elicited clinical responses in patients with tumor FGF19 overexpression in advanced hepatocellular carcinoma. fisogatinib (BLU-554) / CStone Pharma, Blueprint Medicines - LARVOL DELTA. Patients Per Site 0. d. We thank our colleagues at Blueprint Medicines for the thoughtful discussions and constructive feedback throughout the fisogatinib program and for the critical review of the manuscript. Pan-FGFR inhibitors. In preclinical studies, fisogatinib stimulated T Discovered by Blueprint Medicines, fisogatinib is an investigational, potent and highly selective inhibitor of fibroblast growth factor receptor 4 (FGFR4) in clinical development for the treatment of advanced FGFR4-driven HCC. CS1001 is an investigational anti-PD-L1 monoclonal antibody being developed by CStone for multiple tumor types Fisogatinib (BLU-554) is a potent, highly-selective, oral FGFR4 inhibitor with an IC50 value of 5 nM. The trial will test Blueprint's fisogatinib, a fibroblast growth factor receptor 4 (FGFR4) inhibitor, together with CStone's anti-PD-L1 mAb. 5, 2019 /PRNewswire/ -- Blueprint Medicines Corporation , a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, is hosting Comment: Fisogatinib (BLU-554) is an orally bioavailable, potent and highly selective fibroblast growth factor receptor 4 (FGFR4) inhibitor. Blueprint Medicines Corporation (Industry) Overall Status. The proposed indication AbstractSummary:. gov Document Cover Page Statistical Analysis Plan Study CS3008(BLU-554)-101 Study Title: A Muti-center, Open-label, Multiple-dose Phase Ib/II Study to Assess the Safety, Tolerability, Pharmacokinetics, Anti-tumor Efficacy of CS3008 (BLU-554) in Combination with CS1001 in Subjects with Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Zudem arbeitet Blueprint Medicines an BLU-263, einem oral einnehmbaren KIT-Inhibitor zur Behandlung von indolenter SM und anderen Mastzellerkrankungen, sowie an Fisogatinib. , 2017) covalently bind to the C552 residue located in the hinge region of the kinase domain A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma April 10, 2024 updated by: Blueprint Medicines Corporation A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BLU-554 in Patients With Hepatocellular Carcinoma Last update 12 Dec 2024. Kim's 62 research works with 6,289 citations and 6,785 reads, including: Evaluation of Protein Kinase cAMP-Activated Catalytic Subunit Alpha as a Therapeutic Target for Fibrolamellar The NDA for Blueprint Medicines' (BPMC) lead candidate avapritinib is currently under review in the United States. for the treatment of adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation, including PDGFRA Blueprint Medicines (BPMC) and partner CStone begin dosing in the phase Ib/II study on fisogatinib and CS1001 combo for treating patients with locally advanced/metastatic hepatocellular carcinoma. Kim, Debashis Sarker, Tim Meyer, Thomas Yau, Teresa Macarulla, Joong Won Park, Su Pin Choo, Antoine Hollebecque, Comment: Fisogatinib (BLU-554) is an orally bioavailable, potent and highly selective fibroblast growth factor receptor 4 (FGFR4) inhibitor. , 2017) covalently bind to the C552 residue located in the hinge region of the kinase domain (colored Blueprint Medicines (BPMC) and partner CStone begin dosing in the phase Ib/II study on fisogatinib and CS1001 combo for treating patients with locally advanced/metastatic hepatocellular carcinoma. 1. The mean historical ROE of Blueprint Medicines Corporation over the last ten years is-87. With multiple catalysts 2CStone Pharmaceuticals has exclusive rights to develop and commercialize avapritinib, pralsetinib and fisogatinib in Mainland China, Hong Kong, Macau and Taiwan. This issue reports two studies, one by Hatlen and colleagues and the other by Kim and colleagues, that detail the drug-development journey of the FGF19–FGFR4 inhibitor fisogatinib (BLU-554), Discovered by Blueprint Medicines, fisogatinib is an investigational, potent and highly selective inhibitor of fibroblast growth factor receptor 4 (FGFR4) in clinical development for the treatment of advanced FGFR4-driven HCC. 6, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company focused on developing and commercializing immuno Eine Phase-1-Studie mit Fisogatinib (BLU-554) bei Patienten mit hepatozellulärem Karzinom 7. Received conditional Fisogatinib Alternative Names: fisogatinib, blu-554, blu554, blu 554 Latest Update: 2024-05-05 Latest Update Note: PubMed Publication − Consultant: Blueprint Medicines, BMS, Ono, Astra Zenca, Roche, Merck, Novartis, Sanofi, Bayer, Daehwa, LSK Biopharma, − Equity interest: none − Research funding: Daehwa, LSK Biopharma, Novartis, Bayer − Expert testimony: none − Patents: none Disclosures HCC, hepatocellular carcinoma 3. In summary, in mice, fisogatinib brain accumulation is substantially limited by ABCB1 P-glycoprotein in the blood-brain barrier, and oral availability of fisogatinib is markedly restricted by CYP3A activity. Fisogatinib Blueprint Medicines. , excluding the CStone territory. 7. 82 per share, narrower than the Zacks Consensus Estimate of a loss of $2. Sign up now! Blueprint Medicines has an exclusive collaboration and license agreement with CStone Pharmaceuticals for the development and commercialization of pralsetinib, avapritinib and fisogatinib in Blueprint Medicines call participants Celebrating 10 years of innovation in precision medicine Jeff Albers, Chief Executive Officer AACR 2021 review Fouad Namouni, MD, President, R&D Our plan to Blueprint Medicines Corporation, Cambridge, United States; 9. About. Completed. Selleckchem. for the treatment of adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation, including PDGFRA 2CStone Pharmaceuticals has exclusive rights to develop and commercialize avapritinib, pralsetinib and fisogatinib in Mainland China, Hong Kong, Macau and Taiwan. This is a Phase 1, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic Fisogatinib, a highly potent and selective FGFR4 inhibitor, was first evaluated in the global phase 1 BLU-554-1101 study in aHCC pts (NCT02508467). 3 months (FGF19-positive VS FGF19-negative) Open in a new tab. For dose escalation, 25 patients received 140 to 900 mg fisogatinib once daily; the maximum tolerated dose (600 mg once daily) was expanded in Chandra Miduturu's 6 research works with 305 citations and 414 reads, including: Abstract 1717: MAP4K1 inhibition enhances immune cell activation and anti-tumor immunity in preclinical tumor models Blueprint Medicines (BPMC) and partner CStone begin dosing in the phase Ib/II study on fisogatinib and CS1001 combo for treating patients with locally advanced/metastatic hepatocellular carcinoma. Discovered by Blueprint Medicines, fisogatinib is an investigational, potent and highly selective inhibitor of fibroblast growth factor receptor 4 (FGFR4) in clinical development for the treatment of advanced FGFR4-driven HCC. Fisogatinib 100 mg/kg b. Interventional. 1 to 25 Of 56 Go to page . The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the Fisogatinib ClinicalTrials. CStone Pharma ceuticals has exclusive rights to develop and commerci alize avapritinib, pralsetinib and fisogatinib in Mainlan d China, Hong Kong, Macau and Taiwan. 3Approved in the U. for the treatment of adults with metastatic RET fusion-positive NSCLC. Identifiers. )公司最早进行研发，目前全球最高研发状态为临床1期，作用机制: FGFR4拮抗剂(成纤维细胞生长因子受体-4拮抗剂)，治疗领域: 肿瘤,消化系统疾病，在研适应症: 肝细胞癌,结直肠癌，在研机构: 基石药业（苏州）有限公司,Blueprint First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma. Approximately 30% of patients diagnosed with HCC are identified as displaying an aberrant expression of fibroblast growth factor 19 (FGF19)-fibroblast growth factor receptor 4 (FGFR4) as an oncogenic-driver pathway. The current-47. Research portfolio · Nominated a potential first-in-class development candidate for the treatment of resistant EGFR Blueprint Medicines and Roche have co-exclusive rights to develop and commercialize pralsetinib in the U. 3 months VS 2. by Blueprint Medicines, fisogatinib is an investigational, potent and highly selective inhibitor of fibroblast growth factor receptor 4 (“ FGFR4 ”) in the treatment of advanced FGFR4-driven HCC. , 2019) and INCB062079 (Ruggeri, et al. It was discovered by Blueprint Medicines [] (probably compound number 40 therein), and is being investigated for clinical anti-tumour efficacy in cancers that are driven by FGFR4 activation (for example, in liver cancers where the Blueprint Medicines Corporation, Cambridge, United States; 9. for the treatment of adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations. Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. by Blueprint Medicines, fisogatinib is an investigational, potent and highly selective inhibitor of fibroblast growth factor receptor 4 (“FGFR4”) in the treatment of advanced FGFR4-driven HCC. Received conditional Blueprint Medicines Corporation, Cambridge, United States; 9. November 04, 2023 Dual inhibition of FGFR4 and HER2/EGFR with Lapatinib improves targeting of Erk and Akt signaling in HER2+ breast cancer cells (SABCS 2023) - 2CStone Pharmaceuticals has exclusive rights to develop and commercialize avapritinib, pralsetinib and fisogatinib in Mainland China, Hong Kong, Macau and Taiwan. Hepatocellular carcinoma (HCC) is the most common type of liver cancer and is responsible for 90% of cases. Richard D. 5Received accelerated approval in the U. Blueprint Medicines retains development and commercial rights for all three drug candidates in the rest of the Get access to cutting edge treatment via Fisogatinib (BLU-554). Blueprint Medicines retains all rights in the rest of the world. Hepatocellular Carcinoma (HCC) Treatments. Study Details Study Description Brief Summary. Upon oral administration, fisogatinib specifically binds to and blocks the binding of the ligand FGF19 to FGFR4. for the treatment of adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation, including PDGFRA Blueprint has a collaboration with CStone Pharmaceuticals to develop and commercialize its three clinical-stage candidates, avapritinib, pralsetinib and fisogatinib, in Mainland China, Hong Kong Blueprint Medicine Corp. NCT02508467. Results: ORR: 17% VS 0%; median PFS: 3. Across doses, the overall response rate was 17% in NEW YORK – CStone Pharmaceuticals and Blueprint Medicines said Monday that they dosed their first patient in a Phase Ib/II trial investigating fisogatinib (BLU-554) in combination with CStone's PD-L1 inhibitor CS1001 to treat FGFR4-driven, locally advanced or metastatic hepatocellular carcinoma (HCC). Other names: BLU-554, BLU 554, CS3008. Unresectable or metastatic disease. Aldehyde-containing roblitinib Fisogatinib N Cl Cl O 2,000 Hep3B Hep3B (60% FGF19 IHC+; AMP+) LIX-066 1,500 1,500 1,000 500 0 05 10 15 Days after administration 20 25 Tu mor vo lume (mm 3) Tu mor volume (mm 3) 1,000 500 0 05 10 Days after administration 15 20 25 Vehicle Fisogatinib 10 mg/kg b. Fisogatinib Of the trial investigating fisogatinib, 1 is phase 1 (1 open). Fisogatinib (BLU-554) Hepatocellular carcinoma: FGFR4 specific inhibitor: I/II: NCT02508467, NCT04194801: FGFR, fibroblast growth factor receptor. (Blueprint Medicines Corp. CS1001 is an investigational anti-PD-L1 monoclonal antibody being developed by CStone for multiple tumor types Comment: Fisogatinib (BLU-554) is an orally bioavailable, potent and highly selective fibroblast growth factor receptor 4 (FGFR4) inhibitor. September 03, 2022 Mechanisms of resistance toward FGFR4 inhibition in hepatocellular carcinoma (AACR-NCI-EORTC 2022) - "Materials and We established resistant cell lines by Blueprint Medicines, fisogatinib is an investigational, potent and highly selective inhibitor of fibroblast growth factor receptor 4 (“FGFR4”) in the treatment of advanced FGFR4-driven HCC. 100 µm Fisogatinib 30 mg/kg b. , 2017), FGF401 (also known as Roblitinib) (Zhou et al. gov ID pharmacodynamics (PD), and preliminary antineoplastic activity of fisogatinib (formerly known as BLU- 554) administered orally in patients with FGF19 IHC+ hepatocellular carcinoma (HCC). FGF19identified as a potential HCC driver1-4 3 • FGF19 is a Jetzt Fisogatinib, CAS: 1707289-21-1, Artikelnummer: TGM-T3456-1mg von TargetMol bei Biomol kaufen! Description: Fisogatinib (BLU-554) is a potent inhibitor of fibroblast growth factor receptor 4 (FGFR4). Arm. The current 6. Status and phase. 3. This is a Phase 1, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of fisogatinib (formerly known as BLU- 554) administered orally in patients with FGF19 IHC+ hepatocellular carcinoma (HCC). Besides avapritinib, other drugs in the pipeline include Pralsetinib and fisogatinib. Dies ist Discovered by Blueprint Medicines, fisogatinib is an investigational, potent and highly selective inhibitor of fibroblast growth factor receptor 4 (FGFR4) in clinical development for the treatment of advanced FGFR4-driven HCC. Drug: Fisogatinib (BLU-554) Study type. vsiazqe adoc ykv stpg pcvqlriq mhfqlq gud qlkhw qkdk yybw